AstraZeneca PLC 11 February 2021 07:00 GMT Full-year 2020 results Accelerating the scientific and commercial evolution; 2021 guidance shows continuing progress AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. Commentary, Norway Suspends AstraZeneca's Covid-19 Vaccine Over Blood Clot Fears, AstraZeneca COVID-19 Vaccine Batch Suspended In Austria, EU, Italy Block AstraZeneca COVID-19 Vaccine Shipment To Australia, US Court Rules In Favour Of AstraZeneca In Symbicort Patent Litigation With Mylan, Kindeva, Lyft And Uber To Share Information About Driver Deactivations For Safety Issues, Deutsche Bank: 2020 Variable Compensation For Entire Bank Up 29%, Apple Sues Former Employee For Allegedly Stealing Trade Secrets, MG Foods Recalls Turkey Sandwiches For Listeria Concerns, Lifetime Products Recalls 6-Foot Seminar Tables, K+S Stock Up On Higher FY21 Earnings View, Despite Weak Q4 Results, Kia Recalls Nearly 380,000 Vehicles For Fire Risk, Disney+ Surpasses 100 Million Global Paid Subscribers In 16 Months, Campbell Soup Company Q2 Profit Matches Estimates; Net Sales Up 5%, FDA Approves AVEO Oncology's Fotivda For Renal Cell Carcinoma, Thoma Bravo To Commence Tender Offer To Acquire Talend - Quick Facts, PayPal To Buy Crypto Security Firm Curv To Boost Crypto Adoption, Stock Alert: Exela Technologies Surges 150%, Lumentum Amends Agreement To Acquire Coherent In $6.6 Bln Cash & Stock Deal, Akerna To Acquire Viridian Sciences - Quick Facts, MediciNova Partners With BARDA To Develop Chlorine Gas-induced Lung Injury Treatment; Stock Surges, Roche: REMDACTA Trial Fails To Meet Endpoints In Patients With Severe COVID-19 Pneumonia, Novartis: Phase III CANOPY-2 Trial Of Canakinumab Fails To Meet Primary Endpoint, Bausch Health Promotes Sam Eldessouky To Succeed Paul Herendeen As CFO - Quick Facts, Abbott Pandemic Defense Coalition Formed For Early Detection Of Future Pandemic Threats, ANI Pharma To Buy Novitium Pharma For $163.5 Mln - Quick Facts, Genome Signs Deal With Merck KGaA And Pfizer For Immuno-oncology Microbiome Study, Cyclo Gets Positive Opinion From EMA Committee On Agreement Of PIP For Trappsol Cyclo; Stock Up, Chevron Targets More Than Doubling Return On Capital Employed By 2025, Barnes & Noble Education Posts Wider Loss In Q3, DICK'S Sporting Guides FY21 In Line With Estimates; Boosts Dividend 16% - Quick Facts, SNC - Lavalin Group Q4 adjusted earnings of -C$1.53 per share, ANI Pharmaceuticals, Inc. Q4 adjusted earnings Miss Estimates, Mediterranean Food Recalls "Alqosh Sesame Oil", Entain Receives All Necessary Approvals For Enlabs Takeover, Standard Life Aberdeen FY Pre-tax Profit Climbs. Schaeffler India Limited announces Q4 and Full Year results for the period ended December 31, 2020: Posted On: 2021-02-16 09:38:29 (Time Zone: Arizona, USA) endobj
Splits, Earnings
For comments and feedback contact: editorial@rttnews.com, Biotech Stocks Facing FDA Decision In January 2021, EMA: AstraZeneca Vaccine's Benefits Outweigh Blood Clot Risks; Can Continue Vaccination, Sanofi, Translate Bio Start Phase 1/2 Clinical Trial Of MRNA COVID-19 Vaccine Candidate, Johnson & Johnson's Single-dose COVID-19 Vaccine Gets Conditional Marketing Authorization In EU, Johnson & Johnson' Single-dose COVID-19 Vaccine Recommended For Use In EU, More Doses Of Johnson & Johnson's Covid-19 Vaccine For US. News, Stock
ET. Tribal Economic Impact 2019: Focus on Gaming. Annual Reports . In London, AstraZeneca shares were trading at 7,395 pence, up 2.04 percent. Approvals, US
Core earnings per share were $1.07, up 19 percent. Total revenue, comprising Product Sales and Collaboration Revenue, increased 11 percent to $7.41 billion from last year's $6.66 billion. Tribal Economic Impact 2020. Health, Newswires &
4 0 obj
Further, the company has declared a stable second interim dividend of $1.90 per share or 137.4 pence, resulting in a stable full-year dividend per share of $2.80 or 207.0 pence. x��}[��Fr� ��z�t�5�/{���:��Zil���CMOuwa���ճ���;#2�dUF�l2J����E���o����]m.��?��������f�q����������۟7��~�p����{���n>n? 2019. 3 0 obj
Shares of AstraZeneca Plc were gaining around 2 percent in London trading as well as in pre-market activity on Nasdaq after the British drug major projected higher core earnings and revenues in fiscal 2021 after reporting strong fourth-quarter results. Feeds, Digital Signage
Services, Breaking
Copyright © 2021 RTTNews. AstraZeneca (AZN) anticipates having Phase 3 trial results by the end of March, potentially giving the U.S. another vaccine option in coming months. 1 0 obj
endobj
endobj
}���o߭���ź����\+Um�����/��W�_~���/�x��Z�b����/��X���f�����ҫ�w��~�V�O���k�[��×_��lu�?�����/���ӗ_L ��C�Q�4��t@%��T-!f��O�Vo�)��a���g������g]g�����������z�F�ή�;����h��1�3��?jV��.a�x���*���a%=�θu�gϭ�ڭ�Z;ݧm�
nU⯪lIT�$3� <>
%����
FibroGen Inc (NASDAQ:FGEN) Q4 2020 Earnings Call Mar 1, 2021, 5:00 p.m. Veterans in the Workforce 2018. Veterans in the Workforce 2019. Contributor. Download our Annual Report and Form 20-F Information 2020. Calendar, Drug
PDF 12,602KB View online summary. Oslo (Norway), 24 February 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full year 2020 results. <>/Metadata 17804 0 R/ViewerPreferences 17805 0 R>>
Events, Industry
Separately, AstraZeneca announced that non-executive directors Geneviève Berger and Graham Chipchase intend to retire from the Board at the conclusion of the Annual General Meeting on April 30, after serving nine years on the Board. In pre-market activity on Nasdaq, the shares were gaining 1.7 percent to trade at $50.84. Services, Radio News
... You are now leaving AstraZeneca.com. Pascal Soriot - Executive Director and Chief Executive Officer. Full-year 2020 results - Roadshows and conferences. Ladies and … *���=��5������U�� �o��,����q�Oqv�ظ0`��)�. News, Key Wallstreet
AstraZeneca’s (AZN Quick Quote AZN - Free Report) fourth-quarter 2020 results were impressive as it beat estimates for earnings as well as sales.The company also issued guidance for 2021. In fiscal 2020, core earnings per share were $4.02 and total revenues were $26.62 billion, both higher than the previous year. The Opioid Crisis. Earnings per share were $0.78, up from $0.24 last year. Tribal Economic Impact 2019. View all events. In fiscal 2020, core earnings per share were $4.02 and total revenues were $26.62 billion, both higher than the previous year. )��y�3ǒW��xnS�0�����V�����W��1������b��[�,��s�Os�L!þ��� �έ�@�TÞ�g���[)v�+��k�B�\���^��Ob�M9021���㑑�v\��귘H�-;��z(9� =��s����$F���%{��X�]�2�1���"�+��%T�ys���9�8�˨z���nϛ�� stream
AstraZeneca PLC (NASDAQ:AZN) Q4 2020 Earnings Conference Call February 11, 2021 6:45 AM ET. Product sales improved 12 percent to $7.01 billion. Events, Stock
<>
%PDF-1.7
<>/ExtGState<>/XObject<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 21 0 R] /MediaBox[ 0 0 595 842] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>>
�>a��ԭ������{��������x����������o�X����W�$�'���}�t^����O��8������Rg[��{�O�t��ۼz�2D)e�5G��O�Rⶥa~>�����NД��E-�Z���~Kou�^W����������� ��88]s�j]U,��a�^���߳���~ƽ�{Y��3�����? US revenues climbed 15 percent, and revenues from Europe went up 17 percent. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Approvals, Mental
Key Wallstreet
PDF 2,918KB. Company Participants. On a geographical basis, revenues grew 7 percent in Emerging Markets with strong 15 percent increase in China. Looking ahead for fiscal 2021, the company projects total revenue to increase by a low-teens percentage at constant exchange rates, accompanied by faster growth in Core earnings per share to $4.75 to $5.00. Calendar, Drug
2020. 2 0 obj
For the fourth quarter, profit before tax was $1.17 billion, significantly higher than last year's $240 million. The company said the guidance excludes any revenue or profit impact from sales of COVID-19 Vaccine AstraZeneca (C19VAZ), as well as the proposed acquisition of Alexion Pharmaceuticals, Inc., anticipated to close in the third quarter. Hutchison China MediTech Limited Q4 2020 Earnings Call Mar 4, 2021, 8:00 a.m. ET. Revenues increased 10 percent at constant exchange rates. Oncology revenues climbed 24 percent from last year to $3.27 billion, and BioPharmaceuticals revenues grew 3 percent to $2.79 billion. AstraZeneca Stock Up On Strong Q4 Results, Positive FY21 View . All rights reserved. Splits, Earnings